Innate Pharma SA SEC filings IPHYF

Innate Pharma SA has 339 filings in SEC EDGAR's recent list, going back to Jan 31, 2014. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026. The company's fiscal year ends on December 31.

Innate Pharma SA SEC filings
Form Description Filed Period
20-F Annual report (foreign issuer) Apr 1, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Apr 30, 2025 Dec 31, 2024
20-F Annual report (foreign issuer) Apr 4, 2024 Dec 31, 2023
20-F/A Amended annual report (foreign issuer) Apr 20, 2023 Dec 31, 2022
20-F Annual report (foreign issuer) Apr 6, 2023 Dec 31, 2022
20-F Annual report (foreign issuer) Apr 4, 2022 Dec 31, 2021
20-F Annual report (foreign issuer) Apr 27, 2021 Dec 31, 2020
20-F Annual report (foreign issuer) Apr 24, 2020 Dec 31, 2019

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IPHA (Nasdaq), IPHYF (OTC)
Fiscal year ends
December 31
Incorporated in
France
Headquarters
Marseille
SEC filer status
Accelerated filer
SEC CIK
1598599
Former names
Innate Pharma, SA (until Jan 31, 2014)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.